Laserfiche WebLink
of <br />the <br />cost <br />are <br />often <br />= <br />on <br />mostly <br />control <br />by <br />277% <br />(Compounds <br />limit <br />prove <br />Utilization <br />members <br />and <br />amount <br />a <br />by <br />set <br />is <br />to <br />Class <br />to <br />regulated <br />Trend <br />cost <br />drug <br />to <br />studies <br />effectiveness) <br />is <br />Class <br />covered <br />compounds <br />of Market <br />36 <br />inin <br />compounds <br />Unknown <br />IncreasedIncreased <br />class <br />= <br />$86,743 <br />no <br />FDA <br />178.6% <br />total <br />The <br />have <br />This <br />not <br />Therapeutic <br />The <br />increased <br />increase <br />being <br />65% <br />therapeutic <br />the <br />80 <br />with <br />to <br />are <br />is <br />members <br />by <br />attribute <br />agents <br />which <br />agents <br />cost <br />class <br />mostly <br />total <br />10 <br />cost <br />1 <br />Ten <br />Diabetic <br />number <br />Review <br />utilizing <br />19.6% <br />Diabetic <br />top <br />Facts <br />classes <br />driven <br />script <br />Rx <br />The <br />ofby <br />Top <br />The <br /> <br />